organophosphonates has been researched along with Hypertension, Pulmonary in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de la Torre, J; del Arco, A; Olalla, J; Pombo, M; Prada, JL; Urdiales, D | 1 |
| Chai, CY; Chen, IJ; Chou, SH; Dai, ZK; Hsieh, CC; Jeng, AY; Tan, MS; Wu, BN; Wu, JR; Yeh, JL | 1 |
| Ayach, B; Battistini, B; Blouin, A; Cernacek, P; Jeng, AY; Opgenorth, T; Tsang, J; Verreault, M; Wessale, J | 1 |
3 other study(ies) available for organophosphonates and Hypertension, Pulmonary
| Article | Year |
|---|---|
[Pulmonary hypertension in human immunodeficiency virus-infected patients: the role of antiretroviral therapy].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Hypertension, Pulmonary; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Tricuspid Valve Insufficiency; Ultrasonography | 2014 |
Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat.
Topics: Animals; Aspartic Acid Endopeptidases; Blood Pressure; Endothelin-1; Endothelin-Converting Enzymes; Hypertension, Pulmonary; Lung; Metalloendopeptidases; Neprilysin; Nitric Oxide Synthase Type III; Organophosphonates; Protease Inhibitors; Pulmonary Artery; Rats; Rats, Wistar; Tetrazoles; Up-Regulation | 2010 |
Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model.
Topics: Acute Disease; Animals; Aspartic Acid Endopeptidases; Atrasentan; Benzofurans; Cardiovascular Agents; Disease Models, Animal; Embolism, Air; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-Converting Enzymes; Endothelins; Hemodynamics; Hypertension, Pulmonary; Male; Metalloendopeptidases; Organophosphonates; Protease Inhibitors; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Time Factors; Ventricular Dysfunction, Right | 2004 |